Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Vical (NAS: VICL) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Vical and see what CAPS investors are saying about the stock right now.
San Diego, Calif. (1987)
CEO Vijay Samant (since 1990)
Return on Equity
$86.9 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 8% of the 178 members who have rated Vical believe the stock will underperform the S&P 500 going forward.
Vical has concluded yet again that patients in the phase III trial of Allovectin-7 are living longer than expected, resulting in another lengthy delay before topline data will be released. Naturally, Vical bulls see this as a positive, concluding that it is an indicator that patients are living longer in the treatment arm. That sounds like an old story that I heard earlier this year with [Keryx Pharmaceuticals (NAS: KERX) ] and perifosine, with an unfortunate outcome for the bulls. I believe I've seen similar outcomes from prolonged phase III trials previously, but I can't remember one where the bull thesis turned out to be correct.
I've seen many phase III clinical trials fail against melanoma. It's a bad cancer to bet against and I won't start with Vical.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Vical Will Keep Plunging originally appeared on Fool.com.
Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.